3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
21
Recruiting
6
Terminated
5
Withdrawn
2
Active not recruiting
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
CNS
1
Conditions
Breast Neoplasms
2
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
neratinib
×
Clear all
NCT04901299
2023-08-01
HER2-Signal
Massachusetts General Hospital
Phase 2
Withdrawn
NCT04856475
2022-03-02
NeraBrain
Jules Bordet Institute
Phase 2
Withdrawn